Finanzen von SpyGlass Pharma Inc (SGP)SGPSpyGlass Pharma Inc

In the context of the broader market, SGP competes directly with industry leaders such as FTH and CLYM. With a market capitalization of $876.34M, it holds a significant position in the sector. When comparing efficiency, SGP's gross margin of N/A stands against FTH's N/A and CLYM's N/A. Such benchmarking helps identify whether SpyGlass Pharma, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $19.9 million for Q2 2026, a significant increase from the previous year, indicating rising expenses. However, the current ratio remains strong at 25.06, suggesting good short-term liquidity.